Adult Brain Tumor Tools Fail Younger Patients, Study Finds

Adolescent and young adult (AYA) patients, despite comprising a significant portion of those affected by meningioma—the second most common primary brain tumor in this demographic—remain severely underrepresented in neuro-oncology research. While DNA methylation-based classification and prognostic tools have revolutionized meningioma care for adults, their applicability to younger populations remained largely unevaluated. This study embarked on a crucial mission: to assess the performance of these established molecular tools across different age groups, spanning pediatric, AYA, and adult cohorts.

Analyzing 1,568 meningiomas with comprehensive DNA methylation and clinical data, researchers found striking differences. Although histologic grading was comparable, P/AYA tumors exhibited significantly fewer aggressive molecular groups and a lower incidence of chromosomal arm losses, such as 1p, 6q, and 14q, compared to adult tumors. Crucially, a recurrence predictor model trained on adult patients failed dramatically in the P/AYA population, demonstrating poor predictive accuracy. However, when the model was retrained on an age-specific cohort using the same analytical framework, its performance improved substantially, enabling effective stratification of progression-free survival. The retention of prognostic significance for 1p loss within the P/AYA group further highlighted specific molecular markers relevant to younger patients.

As lead author Yefet notes in the paper, "Molecular tools developed in adult-dominant cohorts do not generalize to younger patients due to both biological divergence and exclusion from model development." These findings underscore the urgent need for age-specific molecular frameworks in neuro-oncology. Prioritizing the inclusion of pediatric and AYA populations in future precision oncology research is imperative to ensure that all patients, regardless of age, receive lifespan-equitable and effective care.